These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448 [TBL] [Abstract][Full Text] [Related]
4. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Donepudi M; Jovasevic VM; Raychaudhuri P; Mokyr MB Cancer Immunol Immunother; 2003 Mar; 52(3):162-70. PubMed ID: 12649745 [TBL] [Abstract][Full Text] [Related]
5. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells. Sojka DK; La Motte RN; Mokyr MB Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862 [TBL] [Abstract][Full Text] [Related]
6. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. Jovasevic VM; Mokyr MB J Immunol; 2001 Nov; 167(9):4895-901. PubMed ID: 11673494 [TBL] [Abstract][Full Text] [Related]
7. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Gorelik L; Mokyr MB Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194 [TBL] [Abstract][Full Text] [Related]
8. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Gorelik L; Prokhorova A; Mokyr MB Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831 [TBL] [Abstract][Full Text] [Related]
9. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. Jovasevic VM; Gorelik L; Bluestone JA; Mokyr MB J Immunol; 2004 Feb; 172(3):1449-54. PubMed ID: 14734721 [TBL] [Abstract][Full Text] [Related]
10. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442 [TBL] [Abstract][Full Text] [Related]
11. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases. Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932 [TBL] [Abstract][Full Text] [Related]
12. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174 [TBL] [Abstract][Full Text] [Related]
13. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy. Adler A; Altbaum I J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275 [TBL] [Abstract][Full Text] [Related]
14. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Takesue BY; Pyle JM; Mokyr MB Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Weiskirch LM; Bar-Dagan Y; Mokyr MB Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116 [TBL] [Abstract][Full Text] [Related]
16. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. Gorelik L; Rubin M; Prokhorova A; Mokyr MB J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732 [TBL] [Abstract][Full Text] [Related]
17. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Weiskirch LM; Mokyr MB Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847 [TBL] [Abstract][Full Text] [Related]
18. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189 [TBL] [Abstract][Full Text] [Related]
19. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan. Barker E; Mokyr MB Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124 [TBL] [Abstract][Full Text] [Related]
20. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor. Bartik MM; Takesue BY; Mokyr MB Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]